{
  "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583",
  "docSlug": "f06b0b5d2079",
  "documentTitle": "Soleno Therapeutics (SLNO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-08-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 184,
  "pageCount": 415,
  "prevPage": 183,
  "nextPage": 185,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "The slide uses an excerpt from an FDA label to critique the clinical trial evidence supporting a drug's efficacy.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "data_table",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/184",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-184",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Thus, the flimsy foundation upon which DCCR’s efficacy rests is a worsening of hyperphagia, as assessed by HQ-CT scores, in the placebo group over 16 weeks.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c3-d115994d2ae6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.86,
        "x": 0.07,
        "y": 0.3
      },
      "kind": "image",
      "text": "Clinical Studies text excerpt from FDA label",
      "attrs": null,
      "subkind": "screenshot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e51da8b-2b34-4968-b2d9-208dc96898af",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "HQ-CT Total Score: -5.0",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd953-70f3-714d-84c3-d54f802ba275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.35,
        "x": 0.07,
        "y": 0.26
      },
      "kind": "paragraph",
      "text": "FDA label – Clinical Studies section, excerpts",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78e0a323-d2b9-4292-a0a5-47ff295f1142",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.45,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216665s000lbl.pdf",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "83c5a05c-95cb-45e3-b00c-9f7145517aee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.75,
        "x": 0.07,
        "y": 0.63
      },
      "kind": "table",
      "text": "Table 5: Study 2-RWP HQ-CT Total Score, Least Square Mean Change from Baseline to the End of the Randomized Withdrawal Period (Week 16) in Patients with Hyperphagia and PWS",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8ed4fb19-3f6b-4c41-9acc-f8fda236e11a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "title",
      "text": "The FDA label indicates that the C602-RWP withdrawal study was the pivotal. The Clinical Studies section omits mention of the DESTINY PWS phase 3 and includes only the HQ-CT score changes from RWP. Thus, the flimsy foundation upon which DCCR’s efficacy rests is a worsening of hyperphagia, as assessed by HQ-CT scores, in the placebo group over 16 weeks.",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e232360c-b794-44ef-812a-4f06aa2cb93d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "f402d688-32df-4106-a25d-d2c43d225faa",
      "evidence": "The slide explicitly frames the clinical data as a 'flimsy foundation' and highlights omissions in the FDA label to expose a potential contradiction in efficacy claims.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}